Melbourne, Australia (21 May, 2010). Verva Pharmaceuticals Ltd. (“Verva” or the “Company”) today announced the results of its Annual General Meeting, held at the offices of Middletons Lawyers in Melbourne on 14 May 2010.
Verva financial statements were noted and the current status, progress and strategy of the Company were elaborated in presentations by Verva’s Board chair Dr. Ian Nisbet and CEO Vince Wacher.
Shareholders at the AGM elected Professor Michael Cowley, Dr. John Kurek and Mr. Matthew Morgan to Verva’s Board of Directors.
There were no other resolutions for shareholder approval.
About Verva Pharmaceuticals Ltd.
Verva Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company developing novel therapies to treat diabetes and to prevent and treat obesity. Verva’s lead product VVP808 is a non-thiazolidinedione insulin sensitiser undergoing phase 2a clinical safety and efficacy testing in type 2 diabetes. VVP808 was previously approved in North America in an unrelated indication. Its unexpected anti-diabetic activity was identified using Verva’s proprietary GES discovery platform. Verva’s pipeline includes: (i) an accelerated discovery program developing next-generation diabetes therapies based on VVP808 structure and mode-of-action and (ii) preclinical proof-of-concept with two obesity-focused technologies that block de novo fat formation. Further information can be found on the Company’s website www.vervapharma.com.
|
Verva Contact: |
|
Vince Wacher CEO USA: +1 (760) 271-4783 Australia: +61 (448) 871 479 e-mail: vwacher@vervapharma.com |